nach oben

Inflammopharmacology

Erschienen in:

05.02.2019 | Original Article

Auto-immunity profile evaluation during different clinical manifestations of Behçet disease in Algerian patients: effect of corticosteroid treatment

verfasst von: Fatmazohra Djaballah-Ider, Abdelhamid Djaballah, Zineb Djeraba, Samia Chaib, Chafia Touil-Boukoffa

Erschienen in: Inflammopharmacology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

Behçet disease (BD) is a chronic multisystem disease. It stands at the crossroads between the auto-immunity and auto-inflammatory disorders. Our study aims to evaluate corticosteroids therapy effects on serum immunoglobulin isotypes and anti-phospholipid auto-anti-body production in Algerian BD patients with different clinical manifestations.

Methods

We evaluated serum immunoglobulin isotypes and anti-phospholipid (anti-cardiolipin, anti-β2glycoprotein I, anti-prothrombin) auto-anti-body production using Turbidimetric or Luminex platform assays. Our study was conducted in naïve active BD patients and in corticosteroid-treated patients with different clinical manifestations.

Results and discussion

Our results indicate that IgM, IgG, and IgA levels were higher in naïve active patients. The increase in sera isotypes did not differ according to the clinical manifestation, except for IgA production, which was associated with an increased risk of mucocutaneous and ocular involvement. Interestingly, in corticosteroid-treated active patients, no difference was reported between each clinical subgroup. Furthermore,anti-cardiolipin, anti-β2glycoprotein I and anti-prothrombin auto-anti-body levels were elevated in naïve active patients. Contrary to anti-prothrombin, high anti-cardiolipin and anti-β2glycoprotein I, production differed according to the clinical manifestations and was associated with an increased risk of mucocutaneous and ocular involvement. Importantly, corticosteroid therapy significantly reduced these immune markers regardless of the clinical manifestations.

Conclusion

Our results suggest that high IgA production could be a risk marker of uveitis in naïve active patients. Moreover, concomitant high anti-cardiolipin, anti-β2glycoprotein I and anti-prothrombin production is related to an increased risk of mucocutaneous lesions, ocular and vascular involvement. Collectively, our data indicate the importance of evaluating the corticosteroid effect on immune responses associated with BD to ensure an adequate investigation of each related clinical manifestation.

Alekberova ZS, Prokaeva TB, Reshetniak TM et al (2000) Antiphospholipid anti-bodies in Behcet’s disease. Klin Med 78(5):37–38

Ataollahi MR, Aflaki E, Nazarinia MA et al (2012) anti-cardiolipin and anti-neutrophil cytoplasmic anti-bodies in Iranian patients with Behcet’s disease. Iran J Immunol 9(4):241–247PubMed

Bardak Y, Aridoğan BC (2004) The demonstration of serum interleukin 6–8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet’s disease with ocular involvement. Ocul Immunol Inflamm 12(1):53–58CrossRef

Caramaschi P, Poli G, Bonora A et al (2010) A study on thrombophilic factors in Italian Behcet’s patients. Joint Bone Spine 77(4):330–334. https://doi.org/10.1016/j.jbspin.2010.02.022 CrossRefPubMed

Cho SB, Zheng Z, Ahn KJ et al (2013) Serum IgA reactivity against GroEL of Streptococcus sanguinis and human heterogeneous nuclear ribonucleoprotein A2/B1 in Patients with Behçet disease. Br J Dermatol 168(5):977–983. https://doi.org/10.1111/bjd.12128 CrossRefPubMed

Coit P, Direskeneli H, Sawalha AH (2018) An update on the role of epigenetics in systemic vasculitis. Curr Opin Rheumatol 30(1):4–15. https://doi.org/10.1097/BOR.0000000000000451 CrossRefPubMedPubMedCentral

Davatchi F, Shahram F, Chams-Davatchi C et al (2010) Behcet’s disease: from east to west. Clin Rheumatol 29(8):823–833. https://doi.org/10.1007/s10067-010-1430-6 CrossRefPubMed

Direskeneli H (2006) auto-immunity vs auto-inflammation in Behcet’s disease: do we oversimplify a complex disorder? Rheumatology 45(12):1461–1465. https://doi.org/10.1093/rheumatology/kel329 CrossRefPubMed

Djaballah-Ider F, Chaib S, Belguendouz H et al (2012) T cells activation and interferon-γ/nitric oxide production during Behçet disease: a study in Algerian patients. Ocul Immunol Inflamm 20(3):215–217. https://doi.org/10.3109/09273948.2012.671882 CrossRefPubMed

Djaballah-Ider F, Djeraba Z, Chemli M et al (2018) Influence of corticosteroid therapy on IL-18 and nitric oxide production during Behçet’s disease. Inflammopharmacology. https://doi.org/10.1007/s10787-018-0472-2 CrossRefPubMed

Ekşioglu-Demiralp E, Kibaroglu A, Direskeneli H et al (1999) Phenotypic characteristics of B cells in Behçet’s disease: increased activity in B cell subsets. J Rheumatol 26(4):826–832PubMed

El-Ageb EM, Al-Maini MH, Al-Shukaily AK et al (2002) Clinical features of Behçet’s disease in patients in the sultanate of Oman; the significance of antiphospholipid anti-bodies? Rheumatol Int 21(5):176–181CrossRef

Erdağ E, Şahin C, Küçükali Cİ et al (2017) Effects of in vivo and in vitro administration of neuro-Behcet’s disease IgG. Neurol Sci 38(5):833–843. https://doi.org/10.1007/s10072-017-2856-2 CrossRefPubMed

Erdoğan S, Sorgun MH, Yalçındağ N et al (2015) Bilateral optic neuritis in a patient with Behçet’s disease who respond to therapeutic plasma exchange. Saudi J Ophthalmol 29(4):298–300. https://doi.org/10.1016/j.sjopt.2015.05.003 CrossRefPubMedPubMedCentral

Galli M, Comfurius P, Barbui T et al (1992) Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin anti-bodies. Thromb Haemost 68(3):297–300CrossRef

Garcia-Rivero AA, Gonzalez-Argote J, Martínez Larrarte JP et al (2017) Neuroimmunological response in neuro-Behçet’s. Reumatol Clin. https://doi.org/10.1016/j.reuma.2017.02.005 CrossRefPubMed

Gorbacheva V, Ayasoufi K, Fan R et al (2015) B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) mediate CD40-independent help by memory CD4 T cells. Am J Transpl 15(2):346–357. https://doi.org/10.1111/ajt.12984 CrossRef

Guenane H, Hartani D, Chachoua L et al (2006) Production of Th1/Th2 cytokines and nitric oxide in Behçet’s uveitis and idiopathic uveitis. J Fr Ophtalmol 29(2):146–152CrossRef

Gül A (2015) Pathogenesis of Behçet’s disease: auto-inflammatory features and beyond. Semin Immunopathol 37(4):413–418. https://doi.org/10.1007/s00281-015-0502-8 CrossRefPubMed

Hamzaoui K, Hamzaoui A, Guemira F et al (2002) Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol 31(4):205–210CrossRef

Hamzaoui K, Houman H, Ben Dhifallah I et al (2008) Serum BAFF levels and skin MRNA expression in patients with Behçet’s disease. Clin Exp Rheumatol 26(4 Suppl 50):S64–71PubMed

Higashihara T, Okada A, Kusano T et al (2017) A novel case of renal pathergy reaction in a Behçet’s disease patient complicated by IgA vasculitis. BMC Nephrol 18(1):40. https://doi.org/10.1186/s12882-017-0451-7 CrossRefPubMedPubMedCentral

Kandolf-Sekulovic L, Pavlovic MD, Glisic B et al (2005) Adamantiades-Behçet’s disease, deep venous thrombosis and anticardiolipin anti-bodies: report of two cases. J Eur Acad Dermatol Venereol 19(4):484–486. https://doi.org/10.1111/j.1468-3083.2005.01193.x CrossRefPubMed

Kang HJ, Lee YW, Han SH et al (1998) Anticardiolipin and anti-beta2-glycoprotein I anti-bodies in Behcet’s disease. J Korean Med Sci 13(4):400–404. https://doi.org/10.3346/jkms.1998.13.4.400 CrossRefPubMedPubMedCentral

Kang SE, Lee SJ, Lee JY et al (2017) Serum levels of IgG anti-bodies against alpha-enolase are increased in patients with Behçet’s disease and are associated with the severity of oral ulcer, erythrocyte sedimentation rates, and C-reactive protein. Clin Exp Rheumatol 35 Suppl 108(6):67–74PubMed

Kapsimali VD, Kanakis MA, Vaiopoulos GA et al (2010) Etiopathogenesis of Behçet’s disease with emphasis on the role of immunological aberrations. Clin Rheumatol 29(11):1211–1216. https://doi.org/10.1007/s10067-010-1491-6 CrossRefPubMed

Kawakami T, Yamazaki M, Mizoguchi M et al (2009) Antiphosphatidylserine-prothrombin complex anti-bodies in 3 patients with Behçet disease involving superficial vein thrombophlebitis. Arch Dermatol 145(2):171–175. https://doi.org/10.1001/archdermatol.2008.570 CrossRefPubMed

Khairallah M, Accorinti M, Muccioli C et al (2012) Epidemiology of Behçet disease. Ocul Immunol Inflamm 20(5):324–335. https://doi.org/10.3109/09273948.2012.723112 CrossRefPubMed

LeBien TW, Tedder TF (2008) B lymphocytes: how they develop and function. Blood 112(5):1570–1580. https://doi.org/10.1182/blood-2008-02-078071 CrossRefPubMedPubMedCentral

McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLoS Med 3(8):e297. https://doi.org/10.1371/journal.pmed.0030297 CrossRefPubMedPubMedCentral

Mendoza-Pinto C, García-Carrasco M, Jiménez-Hernández M et al (2010) Etiopathogenesis of Behçet’s disease. Auto-immun Rev 9(4):241–245. https://doi.org/10.1016/j.autrev.2009.10.005 CrossRef

Musabak U, Baylan O, Cetin T et al (2005) Lipid profile and anticardiolipin anti-bodies in Behcet’s disease. Arch Med Res 36(4):387–392. https://doi.org/10.1016/j.arcmed.2005.03.019 CrossRefPubMed

Musabak U, Pay S, Erdem H et al (2006) Serum interleukin-18 levels in patients with Behçet’s disease. Is its expression associated with disease activity or clinical presentations? Rheumatol Int 26(6):545–550. https://doi.org/10.1007/s00296-005-0029-8 CrossRefPubMed

Nakanishi K, Yoshimoto T, Tsutsui H et al (2001) Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19:423–474. https://doi.org/10.1146/annurev.immunol.19.1.423 CrossRefPubMed

Ohno S, Ohguchi M, Hirose S et al (1982) Close association of HLA-Bw51 with Behçet’s disease. Arch Ophthalmol Chic Ill 1960 100(9):1455–1458CrossRef

Park SJ, Oh JY, Shin JI (2014) Could increased IgA induced by BAFF be the cause of IgA nephropathy development in Behcet’s disease? Comment on: Behcet’s disease and IgA nephropathy (Rheumatol Int. 2012 Jul; 32(7):2227–9). Rheumatol Int 34(2):283–284. https://doi.org/10.1007/s00296-013-2667-6 CrossRefPubMed

Pereira RM, Gonçalves CR, Bueno C et al (1989) Anticardiolipin anti-bodies in Behçet’s syndrome: a predictor of a more severe disease. Clin Rheumatol 8(2):289–291CrossRef

Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet’s disease. N Engl J Med 341(17):1284–1291. https://doi.org/10.1056/NEJM199910213411707 CrossRefPubMed

Scherrer MAR, Rocha VB, Garcia LC (2017) Behçet’s disease: review with emphasis on dermatological aspects. An Bras Dermatol 92(4):452–464. https://doi.org/10.1590/abd1806-4841.20177359 CrossRefPubMedPubMedCentral

Suzuki N, Sakane T, Ueda Y, Tsunematsu T (1986) Abnormal B cell function in patients with Behçet’s disease. Arthritis Rheum 29(2):212–219CrossRef

Tokay S, Direskeneli H, Yurdakul S et al (2001) Anticardiolipin anti-bodies in Behçet’s disease: a reassessment. Rheumatol Oxf Engl. 40(2):192–195CrossRef

Trottier MD, Newsted MM, King LE, Fraker PJ (2008) Natural glucocorticoids induce expansion of all developmental stages of murine bone marrow granulocytes without inhibiting function. Proc Natl Acad Sci USA 105(6):2028–2033. https://doi.org/10.1073/pnas.0712003105 CrossRefPubMed

Tursen U (2009) Activation markers in Behcet’s disease. Urkderm Arch Turk Dermatol Venerol 43:74–86

Yoon JY, Lee Y, Yu SL et al (2017) Aberrant expression of interleukin-10 and activation-induced cytidine deaminase in B cells from patients with Behçet’s disease. Biomed Rep 7(6):520–526. https://doi.org/10.3892/br.2017.996 CrossRefPubMedPubMedCentral

Zhou ZY, Chen SL, Shen N, Lu Y (2012) Cytokines and Behcet’s disease. Auto-immun Rev 11(10):699–704. https://doi.org/10.1016/j.autrev.2011.12.005 CrossRef

Zivkovic M, Zlatanovic M, Zlatanovic G et al (2011) Anticardiolipin anti-bodies in patients with Behcet’s disease. Bosn J Basic Med Sci 11(1):58–61CrossRef

Zouboulis CC, Büttner P, Tebbe B et al (1993) Anticardiolipin anti-bodies in Adamantiades-Behçet’s disease. Br J Dermatol 128(3):281–284CrossRef

Titel: Auto-immunity profile evaluation during different clinical manifestations of Behçet disease in Algerian patients: effect of corticosteroid treatment
verfasst von: Fatmazohra Djaballah-Ider
Abdelhamid Djaballah
Zineb Djeraba
Samia Chaib
Chafia Touil-Boukoffa
Publikationsdatum: 05.02.2019
Verlag: Springer International Publishing
Erschienen in: Inflammopharmacology / Ausgabe 6/2019
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-019-00567-8

Springer Medizin

Abstract

Background and aims

Methods

Results and discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients

Thymol reduces acetic acid-induced inflammatory response through inhibition of NF-kB signaling pathway in rat colon tissue

Cilostazol add-on therapy for celecoxib synergistically inhibits proinflammatory cytokines by activating IL-10 and SOCS3 in the synovial fibroblasts of patients with rheumatoid arthritis

Zinc and iron complexes of oleanolic acid, (OA) attenuate allergic airway inflammation in rats

Pterodontic acid isolated from Laggera pterodonta suppressed RIG-I/NF-KB/STAT1/Type I interferon and programmed death-ligand 1/2 activation induced by influenza A virus in vitro

Role of cannabinoid receptor 1 and the peroxisome proliferator-activated receptor α in mediating anti-nociceptive effects of synthetic cannabinoids and a cannabinoid-like compound